Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 48Neoplasm Metastasis 11Hereditary Sensory and Autonomic Neuropathies 7Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Ovarian Neoplasms 5Neoplasms 5Triple Negative Breast Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Lymphangioma 3Hyperglycemia 3Head and Neck Neoplasms 3Pancreatic Neoplasms 2Melanoma 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Head and Neck Squamous Cell Cancer 2Endometrial Neoplasms 2Colorectal Neoplasms 2Advanced Breast Cancer 2Vascular Malformations 1Uveal Melanoma 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Stomach Neoplasms 1Solid Tumor 1Skin Diseases, Vascular 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pre-menopausal Breast Cancer 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recurrence × Alpelisib × Clear all
NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

NCT04997902 2025-12-23

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT02155088 2021-04-08

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
118 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT02144038 2020-12-17

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Novartis

Phase 1 Completed
20 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡